AYTU vs. GLTO, SLGL, INDP, VBIV, COCP, GLYC, NERV, TLPH, KALA, and NRBO
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Galecto (GLTO), Sol-Gel Technologies (SLGL), Indaptus Therapeutics (INDP), VBI Vaccines (VBIV), Cocrystal Pharma (COCP), GlycoMimetics (GLYC), Minerva Neurosciences (NERV), Talphera (TLPH), KALA BIO (KALA), and NeuroBo Pharmaceuticals (NRBO). These companies are all part of the "pharmaceutical preparations" industry.
Galecto (NASDAQ:GLTO) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
14.2% of Galecto shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 12.1% of Galecto shares are owned by company insiders. Comparatively, 4.3% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Galecto has a net margin of 0.00% compared to Galecto's net margin of -14.60%. Galecto's return on equity of -31.31% beat Aytu BioPharma's return on equity.
Aytu BioPharma has higher revenue and earnings than Galecto. Aytu BioPharma is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
Galecto has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500.
In the previous week, Aytu BioPharma had 5 more articles in the media than Galecto. MarketBeat recorded 5 mentions for Aytu BioPharma and 0 mentions for Galecto. Galecto's average media sentiment score of 0.72 beat Aytu BioPharma's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.
Aytu BioPharma received 225 more outperform votes than Galecto when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 58.82% of users gave Galecto an outperform vote.
Galecto presently has a consensus price target of $5.33, suggesting a potential upside of 758.69%. Aytu BioPharma has a consensus price target of $5.00, suggesting a potential upside of 70.07%. Given Aytu BioPharma's higher probable upside, equities analysts clearly believe Galecto is more favorable than Aytu BioPharma.
Summary
Aytu BioPharma beats Galecto on 10 of the 16 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aytu BioPharma Competitors List
Related Companies and Tools